Author

Carolyn Sasse

Observed name: C. Sasse

Institution: Astellas Pharma (United States)

Observed institution: Astellas Pharma (United States)

ORCID: 0000-0001-5883-7477

Observed ORCID: 0000-0001-5883-7477

OpenAlex ID: A5084875671

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

2016 · Francisco M Marty, Luis Ostrosky-Zeichner, et al. · The Lancet Infectious Diseases · 714

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

2022 · Christopher J. Hoimes, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 290

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

2020 · Jonathan E. Rosenberg, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 111

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

2021 · Terence W. Friedlander, Matthew I. Milowsky, et al. · Journal of Clinical Oncology · 50

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

2016 · Kyriakos P. Papadopoulos, Javier Lopez-Jimenez, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 45

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

2016 · Al B. Benson, Igor Kiss, et al. · Clinical Cancer Research · 25

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

2020 · Jonathan E. Rosenberg, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 16

Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer.

2020 · Christopher J. Hoimes, Jonathan E. Rosenberg, et al. · Journal of Clinical Oncology · 12

Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).

2022 · Christopher J. Hoimes, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 8

A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab

2023 · Christopher J Hoimes, Thomas W Flaig, et al. · Future Oncology · 3

Baton-Crc: a Phase 2 Randomized Trial Comparing Tivozanib (Tivo) + Mfolfox6 with Bevacizumab (Bev) + Mfolfox6 in Stage Iv Metastatic Colorectal Cancer (Mcrc)

2014 · A. Benson, J.A. Bridgewater, et al. · Annals of Oncology · 3

Supplemental Table 1 from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

2023 · Al B. Benson, Igor Kiss, et al.

Biomarker Appendix from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

2023 · Al B. Benson, Igor Kiss, et al.

Supplemental Table 1 from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

2023 · Al B. Benson, Igor Kiss, et al.

Supplemental Figure 1 from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

2023 · Al B. Benson, Igor Kiss, et al.

Data from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

2023 · Al B. Benson, Igor Kiss, et al.

Works count: 16

Citation count: 1,277

H-index: 8

I10-index: 8